-+ 0.00%
-+ 0.00%
-+ 0.00%

Don't Ignore The Insider Selling In Diaceutics

Simply Wall St·11/19/2026 05:01:44
Listen to the news

We wouldn't blame Diaceutics PLC (LON:DXRX) shareholders if they were a little worried about the fact that Peter Keeling, the Founder & Non-Executive Chairman recently netted about UK£3.3m selling shares at an average price of UK£1.90. That's a big disposal, and it decreased their holding size by 24%, which is notable but not too bad.

Diaceutics Insider Transactions Over The Last Year

Notably, that recent sale by Peter Keeling is the biggest insider sale of Diaceutics shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of UK£1.88. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.

Happily, we note that in the last year insiders paid UK£1.7k for 1.15k shares. But they sold 4.35m shares for UK£8.3m. Over the last year we saw more insider selling of Diaceutics shares, than buying. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

View our latest analysis for Diaceutics

insider-trading-volume
AIM:DXRX Insider Trading Volume November 19th 2026

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that Diaceutics insiders own 23% of the company, worth about UK£37m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Diaceutics Insiders?

Insiders haven't bought Diaceutics stock in the last three months, but there was some selling. And our longer term analysis of insider transactions didn't bring confidence, either. While insiders do own shares, they don't own a heap, and they have been selling. So we'd only buy after careful consideration. Of course, the future is what matters most. So if you are interested in Diaceutics, you should check out this free report on analyst forecasts for the company.

But note: Diaceutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.